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Background: Identification of signaling pathways altered at early stages after cardiac ischemia/reperfusion
(I/R) is crucial to develop timely therapies aimed at reducing I/R injury. The expression of G protein-
coupled receptor kinase 2 (GRK2), a key signaling hub, is up-regulated in the long-term in patients and in
experimental models of heart failure. However, whether GRK2 levels change at early time points following
myocardial I/R and its functional impact during this period remain to be established.
Methods: We have investigated the temporal changes of GRK2 expression and their potential relation-
ships with the cardioprotective AKT pathway in isolated rat hearts and porcine preclinical models of I/R.
Findings: Contrary to the maladaptive up-regulation of GRK2 reported at later times after myocardial
infarction, successive GRK2 phosphorylation at specific sites during ischemia and early reperfusion elic-
its GRK2 degradation by the proteasome and calpains, respectively, thus keeping GRK2 levels low during
early I/R in rat hearts. Concurrently, I/R promotes decay of the prolyl-isomerase Pin1, a positive regulator
of AKT stability, and a marked loss of total AKT protein, resulting in an overall decreased activity of this
pro-survival pathway. A similar pattern of concomitant down-modulation of GRK2/AKT/Pin1 protein levels
in early I/R was observed in pig hearts. Calpain and proteasome inhibition prevents GRK2/Pin1/AKT degra-
dation, restores bulk AKT pathway activity and attenuates myocardial I/R injury in isolated rat hearts.
Interpretation: Preventing transient degradation of GRK2 and AKT during early I/R might improve the
potential of endogenous cardioprotection mechanisms and of conditioning strategies.
© 2019 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
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lResearch in context
Evidence before this study
Acute myocardial infarction (MI) is a major cause of death
and disability. Prompt restoration of blood flow to the is-
chemic area is key for reducing infarct size and mortality,
but can itself trigger additional myocardial damage, termed
reperfusion injury. Despite advances in the protocols allowing
rapid and effective reperfusion in MI patients, therapies ad-
equately targeting reperfusion injury remain elusive. There-
fore, it is crucial to gather information about the status of key
cardiac signaling pathways at early stages after I/R to identify
potential new targets for intervention. G protein-coupled re-
ceptor kinase 2 (GRK2) is a very relevant signaling hub in car-
diac physiopathology, reported to be upregulated in the long-
term in patients and in experimental models of heart failure.
However, whether GRK2 protein levels are altered at early
time points following myocardial I/R, the molecular mech-
anisms involved and the impact of such changes in GRK2-
related signaling networks has not been fully investigated.
Added value of this study
We find that, contrary to the up-regulation taking place
at later time points after MI, GRK2 levels are transiently
reduced during ischemia and at the onset of reperfusion
in rat and porcine preclinical models. GRK2 proteolysis is
achieved by the combined action of proteasome and calpain
protein degradation pathways, by mechanisms involving dy-
namic changes in the phosphorylation status of GRK2. More-
over, we suggest that such early GRK2 proteolysis would have
an impact on the levels of the AKT kinase, a very impor-
tant component of the cardioprotective pathways triggered
in such pathological contexts. GRK2 proteolysis in early I/R
would favor concurrent degradation of the functionally re-
lated Pin1 prolyl-isomerase and AKT proteins, leading to im-
paired overall AKT catalytic ability despite hyper-activation of
remaining protein, resulting in reduced global capacity of this
pathway to counteract cardiac injury. Importantly, preventing
early GRK2/Pin1/AKT degradation by the combined admin-
istration of proteasome and calpain inhibitors can attenuate
I/R-myocardial injury in isolated rat heart models.
Implications
The timely use of calpain and proteasome inhibition may
help to reinforce therapeutic strategies aimed at reducing I/R
injury.
1. Introduction
Acute myocardial infarction (MI) as a result of coronary artery
occlusion is a major cause of death and disability [1,2]. Prompt
restoration of blood flow by means of thrombolytic or primary per-
cutaneous coronary intervention (PPCI) is key for reducing infarct
size and mortality. However, the process of restoring blood flow
can itself trigger additional myocardial damage (termed reperfu-
sion injury), as a result of abrupt changes in pH and calcium home-
ostasis, alterations in metabolic and inflammatory mediators and
sudden burst of reactive oxygen species. These changes can pro-
mote ventricular arrhythmiasmicrovascular obstruction, myocardial
stunning or myocardial death, leading to increased prevalence of
chronic heart failure (HF) in surviving patients [1,3–6].
Whereas the development of systems of care for emergent my-
ocardial reperfusion and advances in PPCI technology are increas-
ingly allowing rapid and effective reperfusion in MI patients, ther-pies adequately targeting reperfusion injury remain elusive and
onstitute one of the top unmet needs in cardiology [2,7,8]. Brief
ycles of myocardial I/R applied either before (ischemic precon-
itioning) a prolonged coronary artery occlusion plus reperfusion
vent or immediately after reflow (ischemic post-conditioning) in
xperimental models can reduce infarct size by activating different
ombinations of endogenous cardioprotective pathways [1,2,4,9].
ctivation of kinases such as AKT and ERK1/2, important com-
onents of the so-called reperfusion injury salvage kinase path-
ay (RISK) pathway, plays a key cardioprotective role, and modula-
ion of this pathway by endogenous mediators or pharmacological
gents has been postulated as a relevant strategy to prevent I/R
njury [1,4,10,11]. Given the limited efficacy of these current ther-
peutic strategies, it is crucial to gather information about the sta-
us of key cardiac signaling pathways at early stages after I/R [6]
o identify potential new targets for intervention.
G protein-coupled receptor kinase 2 (GRK2) is a central regu-
ator of beta–adrenergic and many other G protein-coupled recep-
ors (GPCRs) involved in cardiovascular physiopathology. In addi-
ion, data in different cell types put forward GRK2 as a key regu-
atory node in non-GPCR pathways via the modulation of insulin
nd growth factor signaling, the PI3K/AKT route, MAPK cascades,
O bioavailability or mitochondrial function, which are also instru-
ental in cardiac function and dysfunction (reviewed in [12–17].
n particular, myocardial GRK2 has been reported to participate
n apoptotic pathways after I/R by mechanisms involving its mi-
ochondrial targeting [18,19]. Maladaptive increased GRK2 expres-
ion has been described in the failing human heart of patients and
n experimental models of HF due to chronic hypertensive or is-
hemic disease, and its genetic ablation or inhibition has been re-
orted to be cardioprotective in the long-term in animal models
y reducing adverse post-infarction remodeling, purportedly as a
esult of the integrated actions of GRK2 in myocardial contractile
unction and cardiac metabolism (reviewed in [15,20–23]. How-
ver, whether GRK2 protein levels are altered at early time points
ollowing myocardial I/R, the molecular mechanisms involved and
he impact of such changes in GRK2-related signaling networks has
ot been fully investigated.
We report that, contrary to the up-regulation reported at later
ime points after MI, GRK2 levels are transiently reduced during
schemia and at the onset of reperfusion in preclinical models,
ue to the combined action of proteasome and calpain pathways,
y mechanisms involving dynamic changes in the phosphoryla-
ion status of GRK2. Our data suggest that such early GRK2 pro-
eolysis would favor concurrent degradation of the functionally re-
ated Pin1 prolyl-isomerase and AKT proteins, thus impairing over-
ll AKT functionality and cardioprotection, whereas the combined
dministration of proteasome and calpain inhibitors prevents early
RK2/Pin1/AKT degradation and counteracts I/R myocardial injury.
. Materials and methods
.1. Experimental protocol of ischemia/reperfusion in rats
The experimental procedures conformed to the Guide for the
are and Use of Laboratory Animals published by the United
tates National Institute of Health (NIH Publication Eighth Edi-
ion, 2011) and were approved by the Research Commission on
thics of the Hospital Vall d’Hebron. Male Sprague-Dawley rats
Charles River,Barcelona, Spain) weighing 250 to 300g were anaes-
hetized with sodium pentobarbital (100mg/kg). Hearts were re-
oved, mounted onto a Langendorff apparatus, and perfused with
modified Krebs-Henseleit bicarbonate buffer as previously de-
cribed. Hearts were perfused normoxically for 60min (Nx group)
r for 20min and then subjected to 40min of global ischemia fol-
owed by reperfusion of different duration (I/R group). Ischemic
P. Penela, J. Inserte and P. Ramos et al. / EBioMedicine 48 (2019) 605–618 607
p
c
(
p
c
o
t
m
z
h
n
h
1
s
w
m
s
p
t
o
v
d
[
2
v
w
2
I
(
m
l
a
L
w
4
t
d
c
i
2
n
E
(
n
w
p
(
N
l
v
t
a
0
s
s
t
a
b
b
s
2
y
s
P
(
i
s
w
b
s
t
f
a
S
P
r
w
A
w
a
f
p
l
s
2
(
N
c
w
n
S
c
b
r
P
p
c
2
t
f
s
c
l
f
w
K
c
fi
i
[
p
t
p
(reconditioning protocol consisted of two cycles of 5min of is-
hemia and 5min of reperfusion applied before index ischemia
PreCo group). Ischemic postconditioning was achieved with a
reviously established protocol commenced immediately after is-
hemia consisting of 6 cycles of 10-second reperfusion-10-second
cclusion (PosCo group) [24–26]. In additional groups of hearts,
he membrane-permeable calpain inhibitor SNJ-1945 (Senju Phar-
aceutical Co,Ltd) at 10μM [27], the proteosome inhibitor borte-
omib (Cell Signaling Technology) at 1μM and 10μM, the PI3K in-
ibitor LY-294002 (10μM, Sigma-Aldrich), or the indicated combi-
ations of SNJ-1945; LY-294002 and 10μM bortezomib or their ve-
icle (0.01% DMSO) were added to the perfusion media during the
0min prior to 40min of ischemia and the first 10min of reperfu-
ion.
The selective contractile inhibitor blebbistatin (10μM, Merck)
as added during the first 5min of reperfusion in all the experi-
ents involving ischemia/reperfusion, except in those experiments
pecifically aimed to assess cell death and infarct size. Blebbistatin
revents cell death by reducing the mechanical stress caused by
he excessive and irreversible contractile activation occurring at the
nset of reperfusion. It was used to discard the possibility that any
ariation on the measured parameters was a mere consequence of
ifferences in cell death associated with sarcolemmal disruption
26].
.2. Experimental protocol of ischemia/reperfusion in pigs
Transient myocardial ischemia in pigs was performed as pre-
iously described [28]. Farm pigs (25–30kg) were pre-medicated
ith tiletamine–zolazepam (4–6mg/kg, IM) and xylazine (1–
mg/kg, IM), anaesthetised with propofol-lipuro 1% (1.5–2.5mg/kg,
V, followed by continuous infusion at 11mg/kg/h) and fentanyl
5mg/kg, IV, followed by continuous infusion at 3–6mg/kg/h), and
echanically ventilated. A mid-sternotomy was performed, and the
eft anterior descending (LAD) coronary artery was dissected free
t its midpoint. Lead II of ECG, left ventricular (LV) pressure and
V dP/dt, coronary bloodflow, and regional myocardial function
ere continuously recorded. LAD coronary artery was occluded for
0min followed by 5min or 120min of reperfusion. At the end of
he experiment, animals were sacrificed by a pentobarbital over-
ose (100mg/kg, IV) and myocardial tissue samples from both, the
ontrol region and the area at risk were quickly excised and frozen
n liquid nitrogen.
.3. Myocardial tissue processing
Myocardial rat or porcine tissue was minced and homoge-
ized in 4 vol (v:w) 20mm Tris-HCl (pH7.5), 5mm EDTA, 5mm
GTA, and protease inhibitors. The homogenate was centrifuged
2000×g, 5min, 4 °C) to obtain a clarified post-nuclear super-
atant designated as crude cytoplasmic fraction (SB1). The pellet
as rinsed in the same buffer (1/5 of the initial volume) sup-
lemented with 0.5% NP40, extensively vortexed and centrifuged
850×g, 10min, 4 °C) after 15min ice-cold incubation to obtain a
P40-extracted nuclear fraction (SB2). For determination of GRK2
evels in some conditions, crude cytoplasmic fractions were pre-
iously enriched in GRK2 protein by incubating these fractions in
he presence of 200–250mmol/L NaCl, followed by centrifugation
t 250,000 ×g for 60min and desalting by using Amicon Ultra-
.5 Centrifugal Filter Devices according to the manufacturer’s in-
tructions. For detection of redox states of PKA RIα, myocardial
amples were homogenized using a Polytron grinder with a hypo-
onic buffer as above but supplemented with 100mM maleimide,
nd protein lysates electrophoresed with non-reducing SDS sample
uffer (100mM Tris HCl pH6.8, 4% SDS, 20% glycerol, bromophenollue with 100mM maleimide) or reducing SDS sample buffer (i.e.
upplemented with 5% β-mercaptoethanol).
.4. Western blot and dot blot analysis
Proteins were separated by SDS-PAGE for Western blot anal-
sis or applied directly on nitrocellulose membranes in a single
pot for immunodetection (dot-blot) as previously described [29].
rotein bands were detected by the chemiluminescence method
ECL, Amersham Pharmacia Biotech) or with the Odyssey Imag-
ng Systems (LI-COR Biosciences). Bands were quantified by laser-
canner densitometry with a Biorad GS-700 scanner or by the soft-
are included in the Odyssey Infrared Imaging System. The rab-
it polyclonal antibodies raised against phosho-Ser/Thr-PKA sub-
trate, phosho-Ser/Thr-AKT substrate, pSer473-AKT and AKT and
he mouse monoclonal anti-Acetylated-Lysine antibody were all
rom Cell Signaling Technologies. Rabbit primary antibodies raised
gainst ERK1/2, Lamin B1 and PKA catalytic subunit were from
anta Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Mouse anti-
KA RI-subunit was from BD Transduction Laboratories. Anti-Pin1
abbit polyclonal and GAPDH mouse monoclonal (6C5) antibodies
ere provided by Upstate Biotechnology and Abcam, respectively.
nti-pSer670-GRK2 and anti-pSer685-GRK2 polyclonal antibodies
ere from Biosource International and from Immunoway. Anti-
cetyl-K40-tubulin and anti-tubulin antibodies were purchased
rom SIGMA. GRK2 protein was immunodetected with a rabbit
olyclonal antibody Ab C-15 (sc-562) (Santa Cruz). Vertical dotted
ines in western blots indicate juxtaposed lanes that come from the
ame gel but were non-adjacent.
.5. Determination of Pin1 acetylation
Myocardial tissue was lysed in immunoprecipitation buffer
50mM HEPES pH7.5, 150mM NaCl, 1%Triton, 10% Glycerol, 10mM
aF,1mM sodium orthovanadate, plus protease inhibitors). Upon
entrifugation (15,000×g, 10min), supernatants were incubated
ith a specific anti-Pin1 polyclonal antibody (Upstate Biotech-
ology or Millipore). Immune complexes were resolved in 15%
DS/PAGE and transferred to nitrocellulose membranes. After in-
ubation with antibody anti-Acetyl lysine (Clone 4G12, Millipore),
lots were stripped and reproved with a polyclonal antibodies di-
ected against the immunoprecipitated Pin1 [30]. The amount of
in1 acetylation was normalized to the amount of the immuno-
recipitated protein, and data were represented as the fold over
ontrol normoxic conditions [29,30].
.6. Cell culture and transfection and protein degradation assays
HEK293 were obtained from the American Type Culture Collec-
ion (ATCC) and maintained in DMEM supplemented with 10% (v/v)
oetal bovine serum (FBS) at 37 °C in a humidified 5% CO2 atmo-
phere. Transient transfections with the indicated combinations of
DNA were performed using the Lipofectamine/Plus method, fol-
owing manufacturer’s instructions.
Metabolic labelling and pulse-chase experiments were per-
ormed as described [31]. HEK293 cells previously co-transfected
ith PKA catalytic subunit or empty vector and GRK2wt, GRK2-
220R or GRK2-S685A constructs were labeled by keeping the
ells for 2h in methionine and cysteine-free Dulbecco’s modi-
ed Eagle’s medium (DMEM) and then incubated for 15–30min
n DMEM supplemented with 250μCi/ml of [35S]methionine and
35S]cysteine labeling mixture (NEN Life Science Products).The
lates were washed with phosphate-buffered saline and chased for
he indicated times in DMEM plus 10% fetal bovine serum. The
roteolysis inhibitors lactacystin (Calbiochem, La Jolla, CA), ALLN
Sigma), or PD150606 (Calbiochem), the PKA activator Forskolin
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c(Sigma) or the PKA inhibitor PKI (Calbiochem) were added 90min
before metabolic labeling and maintained during the chase peri-
ods. At different chase times (1−3h), cells were harvested using ra-
dioimmune precipitation assay lysis buffer (20mm Tris-HCl, pH7.5,
150mm NaCl, 1% sodium deoxycholate, 0.5% Nonidet P-40, 0.1%
SDS, with a mixture of protease inhibitors). GRK2 protein was im-
munoprecipitated with a specific rabbit polyclonal antibody AbFP1
previously validated [32]. Immunoprecipitates were resolved by
SDS/PAGE and transferred to PVDF membranes to be treated with
the Enhancer Autoradiography Starter Kit (EABiotech Ltd.) accord-
ing to the manufacturer’s protocol. Band density of 35S-labeled
GRK2 was quantified by laser densitometry analysis and data were
corrected according to total GRK2 protein detected by immunoblot-
ting [32].
2.7. Quantification of cell death
Lactate dehydrogenase (LDH) activity was spectrophotometri-
cally measured in the coronary effluent throughout the reperfusion
period. After 60min of reperfusion, heart slices were incubated at
37 °C for 10min in 1% 2,3,5-triphenyltetrazolium chloride and im-
aged under white light to outline the area of necrosis as previously
described [25]. Previous studies demonstrated that in the Langen-
dorff rat model, reperfusion for 60min is sufficient for acute as-
sessment of infarct size [26,33].
2.8. Statistical analysis
Data analysis was performed using GraphPad Prism for Win-
dows. Means between groups were compared by 2-way or one-a b
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Fig. 1. Ischemia, reperfusion and conditioning treatments trigger marked and dynamic
hearts were exposed to 40min of ischemia alone 40or with preconditioning I40PreCo(I)
of preconditioning (I/R-PreCo) or post-conditioning (I/R-PosCo) interventions as detailed
continuous perfusion without ischemia. (A) GRK2 protein levels were analyzed by west
expression was used as loading control. (B–C) The extent of GRK2 phosphorylation on diff
using phosphosite-specific antibodies. Data were normalized to total GRK2 levels GAPDH
rats per condition. In all panels, data were analyzed by comparing the different experim
ANOVA followed by Bonferroni’s post-hoc test, †p< .05; ††p< .01, †††p< .001]. In addition
∗∗∗p< .001) or between conditioning situations (#p< .05; ###p< .001) [1-way ANOVA anday ANOVA with Bonferroni’s or Tukey’s post hoc test, respec-
ively, or with unpaired Student’s t-test as indicated in the Figure
egends. All results are expressed as mean± SEM.
. Results
.1. GRK2 is degraded in ischemia and reperfusion conditions by
ifferent mechanisms
Potential changes in GRK2 levels were analyzed during my-
cardial ischemia and the early time points following reperfu-
ion, by using a well-established experimental model of cardiac is-
hemia/reperfusion (IR) in isolated rat hearts [24,25,34]. Notably,
0min of ischemia promoted a marked decay in cardiac GRK2
rotein levels compared to control conditions, and GRK2 down-
egulation was maintained after 30min of reperfusion, when a
irca 50% decrease compared to normoxic GRK2 expression was
oted (Fig. 1A). Neither pre- nor post-conditioning conditions, per-
ormed as described previously [24,25], were able to prevent the
schemia-promoted GRK2 down-regulation. These treatments did
ot fully restore GRK2 protein levels during the 30min of reperfu-
ion, although slightly higher kinase levels at early (precondition-
ng) or later (post-conditioning) reperfusion times were observed.
o overt changes in the subcellular distribution of the kinase were
bserved in either I or in I/R experimental conditions (Fig. S1), sug-
esting that the rapid down-modulation of GRK2 levels was related
o protein degradation.
GRK2 can be rapidly degraded by the proteasome, in a pro-
ess dependent on its previous phosphorylation at the S670c
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changes in cardiac GRK2 protein levels and phosphorylation status. Isolated rat
followed by reperfusion for the times indicated (I/R) in the presence or absence
in Methods. Control group (Nx, normoxia condition) was exposed to60 min of
ern-blot with a specific total anti-GRK2 antibody as detailed in Methods. GAPDH
erent residues (Ser670 or Ser685) was monitored in cardiac lysates by western-blot
expression was used as loading control. In all panels, data are mean± SEM, n=3–4
ental situations (I/R, I/R-PreCo and I/R-PosCo) to the normoxic condition [2-way
, we compared I/R pre-Co and I/R post-Co conditions versus I/R alone (∗p< .05;
Tukey’s post hoc test]. Representative blots are shown.
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Fig. 2. Cardiac ischemia/reperfusion induces rapid and transient oxidation-dependent activation of PKA. (A) Global PKA activity was assessed in lysates from normoxic or
reperfused isolated rat hearts (40min of sustained ischemia followed by the indicated reperfusion times) by dot-blot, using a pan-specific phospho-substrate antibody that
broadly detects phosphorylated proteins by PKA as indicated in Methods. GAPDH expression was used as loading control. Data are mean± SEM, n=3–4 rats per condition.
∗∗p< .01; ∗∗∗p< .001 compared to I/R 30min [1-way ANOVA and Tukey’s post hoc test]. A representative dot-blot is shown. (B) I/R promotes oxidation-related dimerization
of the regulatory PKA-RIα subunit in parallel to global PKA activation. Lysates as in panel A were probed with a specific PKA-RI antibody that recognizes both monomers
and dimers of this regulatory subunit linked by disulfide bond formation. The dimer formation detected in non-reducing SDS-PAGE resolving conditions was fully reversed
in the presence of 2-mercaptoethanol (reducing SDS-PAGE). The expression of the PKA catalytic subunit and of GAPDH was used as loading controls. Data are mean± SEM,
n=3–4 rats per condition. ∗p< .05 for the indicated comparisons [Student’s t-test]. Representative blots are shown.
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3esidue [35,36]. Interestingly, a dramatic increase of GRK2 S670-
hosphorylation status was noted in ischemic conditions (Fig. 1B),
pattern consistent with the involvement of the S670-GRK2 phos-
horylation/proteasome pathway in kinase downmodulation dur-
ng this period. However, S670 phosphorylation rapidly returned
o normoxic levels upon reperfusion in all conditions tested, sug-
esting that additional mechanisms were involved in maintaining
RK2 protein levels low during the initial phase of reperfusion.
We searched for other regulatory post-translational modifica-
ions during this period. GRK2 is phosphorylated by PKA on S685,
residue highly conserved across species, leading to increased
inding to Gβγ subunits and subsequent translocation to the
lasma membrane [37]. We uncovered a rapid (1min) and tran-
ient (peak at 5min) increase of GRK2 phosphorylation at S685
pon reperfusion (Fig. 1C). A similar pattern was observed un-
er pre- or post-conditioning conditions, although the extent of
685 phosphorylation was slightly but significantly decreased (pre-
onditioning) or enhanced (post-conditioning) at early reperfusion
imes. The pattern of phospho-S685 GRK2 during early reperfusion
railed the rapid and transient increase in total PKA activity de-
ected in these cardiac samples (Fig. 2A), consistent with previous
eports of PKA activation during I/R as a result of GPCR stimula-
ion or oxidative stress [38,39]. Oxidation-dependent formation of
disulfide bond between the RIα subunit of PKA leading to dimer-
zation can promote PKA activation independently of cAMP [39].
otably, the transient changes in global PKA activity in reperfused
solated rat heart were parallel to those observed in the dimeriza-
ion status of PKA-RIα (Fig. 2B), suggesting that this mechanism of
KA stimulation might play a relevant role in such early reperfu-ion contexts. pThe pattern of total and phospho-S685 GRK2 levels during
eperfusion suggested that this phosphorylation might help to keep
RK2 downregulated. Pulse-chase experiments in HEK-293 cells, a
ell-established model for characterizing GRK2 degradation mech-
nisms [20,35,40], indicated that forskolin (FO), a direct stimu-
ator of adenylyl cyclase activity, and thus of the PKA pathway,
ncreased the basal turnover of GRK2 (Fig. 3A), as well as trig-
ered phosphorylation of GRK2 on S685 (Fig. S2). Interestingly, FO
lso enhanced the degradation of the catalytically-inactive GRK2-
220R mutant (Fig. 3A), previously reported to be impaired in
PCR-induced proteasome-mediated degradation [41]. This sug-
ested that the GRK2-destabilizing effect of FO involved alternative
roteolytic pathways.
It is worth noting that the fostering effect of FO in GRK2 degra-
ation was fully prevented upon addition of a PKA inhibitor (Fig.
2B), whereas over-expression of the catalytic subunit of PKA en-
anced the decay of both wild-type GRK2 and the K220R mutant
Fig. 3B), confirming the involvement of PKA downstream of FO in
he modulation of GRK2 stability. Moreover, a GRK2-S685A mutant
unable to be phosphorylated by PKA) displayed a stability simi-
ar to WT GRK2 in basal conditions, but lacked the PKA-stimulated
omponent of GRK2 degradation, demonstrating that phosphoryla-
ion on S685 was required for PKA activity-induced GRK2 down-
egulation (Fig. 3C).
Consistent with the involvement of alternative PKA-dependent
roteolytic pathways, the proteasome inhibitor lactacystin fully in-
ibited the basal degradation of wt GRK2, whereas only partially
ttenuated GRK2 proteolysis in the presence of FO stimulation (Fig.
D). On the other hand, PKA-triggered GRK2 degradation was com-
letely abrogated upon addition of broad spectrum (ALLN, Fig. 3D)
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cor specific (PD150606, Fig. S2C) inhibitors of calpains, a family
of Ca2 + -dependent cysteine proteases reportedly over-activated in
myocardial reperfusion, leading to myocardial injury through the
proteolysis of different proteins [42–44], suggesting that calpain-
mediated proteolyisis of phospho-S685-GRK2 might take place in
early I/R conditions.
Overall, our data suggested that dynamic and sequential phos-
phorylation of GRK2 at S670 and S685 during ischemia and in early
reperfusion would trigger GRK2 degradation by the proteasome
and via calpains, respectively, thus maintaining low GRK2 protein
levels during such initial period after heart damage.
3.2. AKT degradation takes place in early I/R resulting in decreased
overall activity of this pathway
We investigated whether such transient GRK2 downmodulation
was related to changes in other key cardiac signaling pathways. To-
tal ERK1/2 protein levels were not significantly altered during I/R
or upon pre- or post-conditioning (Fig. S3A), indicating that I/R
does not promote a general decay in signaling proteins. Interest-
ingly however, total AKT protein levels were markedly diminished
by ischemia and maintained low during the first 30min of reper-
fusion (Fig. 4A), with a pattern similar to that detected for GRK2.
Moreover, AKT and GRK2 protein levels displayed a similar trend
of changes upon pre- conditioning, which led to a less markedKT decrease after ischemia and at very early reperfusion times
Fig. 4A). As for GRK2, no manifest changes in the nu-
lear/cytoplasmic distribution of AKT were observed in either I or
n I/R experimental conditions (Fig. S3B), suggesting the occurrence
f protein degradation processes.
Such pattern of decreased AKT protein levels during I/R was
uzzling, since the cardio-protective and pro-survival AKT path-
ay is considered to be robustly enhanced in these conditions
o counterbalance I/R-promoted injury, as inferred from enhanced
KT phosphorylation at activating residues [1,4,11]. In our exper-
mental setting, we also detected such marked increase of stim-
lated (phosphor-S473) AKT during reperfusion and upon pre- or
ost-conditioning conditions (Fig. 4B). However, the concurrent al-
eration in total AKT protein levels appears to have been disre-
arded or not addressed in detail in other studies. Our data point
o a more complex scenario in which I/R triggers both AKT pro-
ein downmodulation and activation of the remaining kinase. No-
ably, when the “global” or bulk AKT activity was tested in car-
iac extracts using a pan-AKT substrate antibody, we observed a
arked decrease throughout the I/R period considered (Fig. 4C),
ith a similar pattern upon post- or pre-conditioning, although the
ater condition allowed slightly higher substrate phosphorylation at
min after reperfusion. Our data indicated that hyper-activation of
he remaining AKT during reperfusion might notbe able to fully
ompensate for the decay in protein levels, leading to a clear over-
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Fig. 4. Ischemia/reperfusion promotes a marked loss of total AKT protein and an overall decrease in global AKT-mediated substrate phosphorylation, despite the robust
stimulation status of the remaining AKT protein. Rat heart lysates as in Fig. 1 were analyzed with specific antibodies for total AKT (A) or for AKT phosphorylated at Ser473
(B) as detailed in Methods. Data were normalized by GAPDH (panel A) or total AKT (panel B) loading. (C) Global activity of AKT towards its substrates was assessed in cardiac
lysates from the indicated conditions by dot-blot, using a pan phospho-AKT substrate-specific antibody, and data normalized by GAPDH loading. In all panels, normalized
data were represented as fold-change with respect to normoxic situation and are mean± SEM, n=3–4 rats per condition. Data were analyzed by comparing the different
experimental situations (I/R, I/R-PreCo and I/R-PosCo) to the normoxic condition (2-way ANOVA followed by Bonferroni’s post-hoc test, †p< .05; ††p< .01, †††p< .001). In
addition, we compared I/R pre-Co and I/R post-Co conditions versus I/R alone (∗p< .05; ∗∗∗p< .001) or between conditioning situations (#p< .05; ##p< .01, ###p< .001)
[1-way ANOVA and Tukey’s post hoc test]. Representative blots are shown.
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lll downmodulation of the “catalytic potency” of this key cardio-
rotective pathway in early I/R contexts, what would counteract
he beneficial effects of treatments specifically aimed at enhancing
he AKT activation status.
In search of molecular mechanisms underlying AKT protein de-
ay and potentially connecting transient GRK2 and AKT downmod-
lation, we focused on the prolyl-isomerase Pin1, a central player
n the control of folding, activity, and stability of proteins [45,46].
in1 is a critical positive factor in the regulation of AKT stability in
ancer cells by binding to activated AKT and preserving the protein
rom degradation by the proteasome [46,47]. Pin1 has also been
escribed as a relevant factor in cardiac hypertrophy, directly bind-
ng to AKT and MEK and fostering hypertrophic signaling [48]. In-
erestingly, we found a clear reduction of Pin1 levels after ischemia
nd during early reperfusion times (Fig. 5A), with a pattern resem-
ling that of AKT protein, suggesting a link between Pin1 loss and
ecreased AKT stability. A similar pattern of Pin1 changes was ev-
dent in nuclear and cytoplasmic cellular fractions, consistent with
in1 degradation events (Fig. S3C).
Interestingly, GRK2 is a regulator of Pin1 stability and function-
lity in other cell types [30]. GRK2 activates HDAC6, a cytoplas-
ic lysine deacetylase targeting tubulin and many other proteins,
hus triggering de-acetylation of Pin1 at a specific residue, there-
ore favoring Pin1 protein stabilization and stimulation of prolyl-
somerase activity [30,49]. We thus assessed whether Pin1 acety-
ation might be triggered upon GRK2 downregulation during I/R.
his treatment induced a marked increase in Pin1 protein acetyla-
ion, which peaked at 5min of reperfusion (Fig. 5B). A similar pat-
ern was detected for the acetylation levels of the canonical HDAC6
ubstrate tubulin (Fig. 5C), strongly suggesting an impaired HDAC6
ctivation by GRK2 in I/R conditions.Importantly, a comparable pattern of concurrent down-
odulation of GRK2, AKT, and Pin1 protein levels in early stages
f myocardial reperfusion was also detected in porcine hearts sub-
ected to in situ transient ischemia. The levels of these proteins in
he area at risk were significantly decreased at 5min of reperfu-
ion with respect to control area of the same animal (Fig. 6A–D).
fter 120min of reperfusion, total AKT and Pin1 protein expres-
ion values were still slightly lower than those of the matched con-
rol area, whereas a marked GRK2 down-modulation remained. In
ine with the mechanistic role of PKA in promoting GRK2 down-
odulation observed in the rat model, increased levels of PKA-
hosphorylated substrates were detected at 120min of reperfu-
ion (Fig. S4). Of note, although an enhanced AKT phosphoryla-
ion status was apparent at these I/R stages (Fig. 6C) as previ-
usly reported in such conditions [50,51], the global or bulk ca-
acity of active AKT to phosphorylate its targets was markedly re-
uced (Fig. 6E), akin to the observed decline in total AKT protein
evels and in line with our data in the isolated rat heart model
see Fig. 4). Although whether such early and dynamic changes
n GRK2/AKT/Pin1 levels take place in patients during cardiac I/R
annot be directly investigated, the data obtained in this relevant
ranslational large animal model supports the potential clinical rel-
vance of these alterations.
.3. Combined use of proteasome and calpain inhibitors prevents
RK2/Pin1/AKT degradation and attenuates I/R myocardial injury
Overall, our data suggested a complex interconnection among
RK2, Pin1 and AKT in early cardiac I/R. Changes in the phospho-
ylation status of GRK2 would trigger transient reduction of kinase
evels by the combined action of proteasome and calpain path-
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∗p< .05, ∗∗∗p< .001 compared to normoxia [1-way ANOVA and Tukey’s post hoc test]. Representative blots are shown.
*
b dc
5 min 120 min
Ctrl
I/R
Ctrl
I/R
AKT 
phospho-substrate
GAPDH
**
*
**
e
*
a
*
***
GRK2
#1 #2 #1 #2 #1 #2 #1 #2
GAPDH
75
MW 
(kDa)
37
Pin1
#1 #2 #1 #2 #1 #2 #1 #2
GAPDH
MW 
(kDa)
37
20
15
AKT
#1 #2 #1 #2 #1 #2 #1 #2
GAPDH37
50
MW 
(kDa)
AKT
#1 #2 #1 #2 #1 #2 #1 #2
pAKT
MW 
(kDa)
50
50
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indicated conditions as in Fig. 4C. Data were normalized with Ponceau protein staining. In all panels, normalized data were represented as fold-change with respect to
normoxic situation and are mean± SEM, n=4 rats per condition. ∗p< .05; ∗∗p< .01; ∗∗∗p< .001 compared with the conditions indicated with the lines [1-way ANOVA and
Tukey’s post hoc test]. Representative blots are shown.
w
i
d
h
c
i
p
i
f
t
t
b
t
7
i
s
r
p
i
A
t
t
t
c
s
l
a
e
i
P
v
t
4
r
i
t
t
u
M
i
G
t
w
A
c
t
d
t
s
a
a
(
c
i
s
s
o
d
i
r
d
2ays. GRK2 degradation would favor Pin1 proteolysis by altering
ts acetylation status, which in turn would facilitate AKT degra-
ation, leading to impaired overall AKT catalytic ability despite
yper-activation of remaining protein, resulting in reduced global
apacity to counteract cardiac injury.
We therefore tested the effect of the administration of the clin-
cally used proteasome inhibitor Bortezomib (Bz) and/or the cal-
ain inhibitor SNJ-1945 (SNJ) on cardiac GRK2, Pin1 and AKT levels
n isolated heartsrats subjected to 40min of ischemia and reper-
usion for 10min. A slight significant prevention of AKT degrada-
ion was observed in the presence of BZ, and a tendency was de-
ected for GRK2 and AKT protection upon administration of SNJ,
ut only the combined treatment with BZ and SNJ fully prevented
he downregulation of GRK2, Pin1 and AKT in such conditions (Fig.
A-C), allowing the maintenance of levels close to those detected
n normoxic conditions. Importantly, the administration of protea-
ome or calpain inhibitors or their combined delivery significantly
escued bulk AKT functionality, as assessed by the overall phos-
horylation of AKT substrates during reperfusion (Fig. 7D). This
s consistent with the fact that these treatments tend to protect
KT protein from degradation while preserving kinase activation
riggered by reperfusion, as indicated by AKT phospho-S473 sta-
us (see representative blot in Fig. 7C), thus allowing a normaliza-
ion of pAKT/AKT ratios. Moreover, the administration of the SNJ
alpain inhibitor or the combined delivery of SNJ and the protea-
ome inhibitor BZ prior to a protocol of 40min of ischemia fol-
owed by 60min of reperfusion significantly decreased infarct size
nd LDH release. Of note, this effect was not observed in the pres-
nce of a PI3K inhibitor, indicating that calpain and proteasome
nhibitors exert its protective action by mechanism involving the
I3K/Akt pathway (Fig. 8A). Overall, our results postulate that pre-
enting GRK2/Pin1/AKT degradation at early times in I/R may help
o counteract myocardial injury.. Discussion
Our data reveal several unforeseen alterations taking place in
elevant cardiac signaling pathways during the early stages of I/R
n rat and porcine experimental models that might provide a ra-
ionale for therapeutic strategies aimed at fostering cardioprotec-
ion mechanisms. First, we uncover that, contrary to the reported
p-regulation of cardiac GRK2 taking place at later times after
I [21–23], successive GRK2 phosphorylation at specific sites dur-
ng ischemia and in early reperfusion would sequentially elicit
RK2 degradation by the proteasome and calpains, respectively,
hus keeping GRK2 protein levels low during early I/R. Second,
e unveil a marked and previously uncharacterized decrease of
KT protein levels during this period, likely related to concurrent
hanges in the Prolyl isomerase Pin1 (a known AKT stabilizing fac-
or), which results in an overall down-modulation of this key car-
ioprotective pathway in early I/R contexts, despite the high ac-
ivation status of the remaining AKT upon reperfusion. Third, we
how that hindering GRK2/Pin1/AKT degradation by the combined
dministration of proteasome and calpain inhibitors can attenu-
te I/R-myocardial injury in isolated ratheart experimental models
scheme in Fig. 8B).
The prevailing view to date is that GRK2 levels are in-
reased in the heart of chronic HF patients with dilated or
schemic cardiomyopathy, as a result of sympathetic nervous
ystem hyperactivity, leading to enhanced GRK2 mRNA expres-
ion. Such augmented GRK2 levels may initially help the my-
cardium to counterbalance the beta-adrenergic overdrive and re-
uce the risk of tachyarrhythmia, but persisting high GRK2 activ-
ty is maladaptive, resulting in GPCR desensitization and down-
egulation, defective contractility, insulin resistance, mitochon-
rial dysfunction and apoptosis, paving the way to HF [13,21,
3].
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Fig. 8. Cardiac ischemia-reperfusion injury is attenuated by combined-inhibition of proteasome and calpain activities. (A) Isolated rat hearts were treated during the 10min
prior to ischemia (40min) and the first 10min of a total period of 60min reperfusion with the indicated combinations of the calpain inhibitor SNJ-1945 (SNJ, 10μM), the
proteasome inhibitor Bortezomib (BZ) (10μM) and the PI3K inhibitor LY-294002 (10μM). After the reperfusion period, total LDH released during reperfusion (expressed as
units of activity released per gram of dry weight during the first 60min of reperfusion, U/gdw/60min) and infarct size (expressed as the percentage of ventricular mass in
the different experimental groups) were determined as detailed in Methods. Data are the mean± SEM, n=6–9 rats per condition. ∗p< .05 vs untreated I/R control group [1-
way ANOVA and Tukey’s post-hoc test]. (B) Scheme of the molecular mechanisms underlying GRK2/Pin1/AKT degradation during myocardial ischemia and early reperfusion.
See text for details.
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dStrikingly, we find that following myocardial I/R, GRK2 pro-
tein levels markedly decrease during the ischemic phase and are
kept low during the early phase of reperfusion. Our data sug-
gest that enhanced Ser670-GRK2 phosphorylation during ischemia
would trigger its degradation by the proteasome, whereas phos-
phorylation at Ser685 taking place in early reperfusion would favor
calpain-mediated GRK2 proteolysis. Of note, these phosphorylation
sites are highly conserved across species, (murine, dog, pig and hu-
mans), consistent with preserved modulatory mechanisms.
To our knowledge, the pattern of GRK2 protein levels at such
initial times of I/R has not been previously described. In murine
models, cardiac GRK2 protein upregulation has been reported as
early as 3 and 7days after acute myocardial injury [13,52]. How-
ever, in line with our results, in a canine model of MI GRK2 levels
were decreased in the subepicardial border and the infarct zone
at 6 and 24h after ligation of the coronary artery, without ap-
parent changes in mRNA levels, and such GRK2 decrease in is-
chemic cardiac tissue was blocked by treatment with proteasome
inhibitors, resulting in a significant cardioprotection against ma-
lignant ventricular tachyarrhythmias [53–55]. In the brain, oxygen
deprivation triggers a marked decrease in GRK2 content along en-
hanced GRK2 phosphorylation at Ser670 in the absence of changes
in mRNA levels, in a process blocked by proteasome inhibitors
[56,57].
Upon phosphorylation at S670 GRK2 can be rapidly degraded
by the proteasome [31,35], and GPCR stimulation facilitates β-
arrestin-dependent ERK1/2 activation and subsequent phosphory-
lation of GRK2 at this residue [35]. Thus, the observed burst in
phospho-Ser670 GRK2 after ischemia points to the occurrence of
a very active proteasome-dependent degradation of the kinase in
this condition. Although an ischemia-triggered inhibition of GRK2
transcription and/or translation cannot be ruled out, a previous
report showed that during stop-flow and low flow ischemia in
the isolated perfused rat heart GRK2 mRNA even increased af-
ter 20min of ischemia and then returned to baseline after 40minf ischemia onset [58], further supporting a predominant role for
RK2 proteolysis in this context.
GRK2 is phosphorylated at S670 by several kinases in a
ontext-and stimulus-dependent way, including ERK1/2 [49,59,60],
38MAPK [61] or Cdk2 [31]. CDK2 is highly activated during my-
cardial ischemia [10,62] and CDK2-mediated GRK2 S670 phospho-
ylation can trigger proteasome-dependent GRK2 degradation in a
PCR-independent way [31], suggesting that this regulatory axis
ould be active during the ischemic phase.
The fact that GRK2 protein levels remained low during early
eperfusion in the absence of enhanced S670 phosphorylation sug-
ested the involvement of an alternative degradation pathway. We
nd that GRK2 is rapidly and transiently phosphorylated by PKA
t S685 upon reperfusion, and that PKA stimulation can trigger
alpain-dependent GRK2 proteolysis in a cellular model. Consistent
ith sequential proteasome and calpain GRK2 degradation during
/R, the combined inhibition of these proteolytic pathways com-
letely prevents GRK2 protein decay in vivo.
Calpains are ubiquitous Ca2 + -dependent cysteine proteases ac-
ivated in pathological conditions associated with Ca2+ overload.
alpains are thus strongly activated at the onset of myocardial
eperfusion, contributing to myocardial injury through the prote-
lysis of key structural membrane, cytoskeletal components and
egulatory enzymes [42,44,63]. Notably, PKA-phosphorylated GRK2
ould only be targeted by calpains during the reperfusion phase
pon intracellular pH normalization, since during ischemia ongo-
ng acidosis inhibits these proteases [42].
However, the functional relationships among PKA stimulation,
alpain activation status and GRK2 degradation are not straightfor-
ard and may involve additional regulatory layers. While phospho-
ylation of GRK2 by PKA switches on degradation by calpain, PKA
as been reported to inhibit calpains upon βAR-triggered cAMP
timulation, and such mechanism appears to participate in the
olecular mechanisms of cardioprotection upon ischemic precon-
itioning [64]. This apparent paradox may be reconciled by the
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hxistence of compartmentalized pools of these proteins and of dis-
inct localization and activation mechanisms of PKA isoforms via
egulatory anchoring proteins termed AKAPs [65]. In the vicinity of
he plasma membrane, βAR-dependent production of cyclic-AMP
eportedly promotes activation of AKAP79-bound type II PKA II
eading to phosphorylation of GRK2 [37] and potentially also cal-
ains, which subsequent inhibition would partially protect sub-
trates such as fodrin and receptor-bound GRK2 from proteoly-
is in such locations. On the other hand, we find that reperfu-
ion, in parallel to increased global PKA activity and S685-GRK2
hosphorylation, enhances the oxidation-dependent dimerization
tatus of PKA-RIα, an event leading to PKA activation indepen-
ently of cAMP and driving its localization at the myofilament
ompartment [39,66], where a significant pool of GRK2 protein
s present via association with sarcomeric a-actinin [67]. We pos-
ulate that PKA-mediated GRK2 phosphorylation at such location
ould particularly favor its subsequent degradation by nearby
alpains, less likely to be targeted there by the reported βAR-
KA inhibitory phosphorylation mechanism. Interestingly, at early
eperfusion times after preconditioning we observed comparatively
igher GRK2 levels and decreased S685 phosphorylation status,
onsistent with diminished oxidation-dependent PKA activation in
uch conditions due to decreased ROS production [68], despite en-
anced βAR-PKA stimulation also taking place in such conditions
64].
The cardio-protective and pro-survival AKT pathway is consid-
red to be up-regulated during reperfusion to compensate I/R-
romoted injury, and enhanced stimulatory AKT phosphorylation
s found in such conditions. Activation of the Akt cascade is cen-
ral to several conditioning strategies and plays a relevant cardio-
rotective role within the reperfusion injury salvage kinase path-
ay (RISK) pathway, whereas inhibitors of the upstream kinase
I3K block conditioning and cardioprotection [1,4,10,11]. However,
e uncover that a concurrent and marked reduction in total AKT
rotein levels is triggered by ischemia and maintained during the
rst 30min of reperfusion, resulting in an overall decrease of
lobal AKT activity in cardiac extracts. The fact that such changes
n total Akt levels at early times of I/R has not been investigated
n detail before may be explained by the circumstance that in
his type of studies total AKT levels are usually employed as load-
ng controls to normalize the pAkt phosphorylation status, with-
ut direct comparison to other loading controls that would allow
ssessing possible changes in Akt protein levels (for instance see
11,51,69–71] However, a few reports do show an apparent de-
rease in total Akt levels compared to normoxia in I/R-related con-
itions [26,72,73] although this fact or the mechanisms involved
ere not discussed in detail.
Our results indicate that hyper-stimulation of the remaining
KT enzyme during reperfusion might not be able to fully com-
ensate for the decay in protein levels taking place during early
/R. Such Akt protein down modulation would thus likely coun-
eract the beneficial effects of therapeutic approaches specifically
imed at fostering Akt stimulation, suggesting that preventing
RK2/Pin1/Akt degradation would safeguard global Akt catalytic
nd foster the efficacy of cardioprotective drugs or conditioning
trategies (see section below).
We postulate that GRK2-related changes in the Prolyl isomerase
in1 may provide functionally link altered GRK2 and AKT protein
evels during I/R. AKT undergoes proteasomal degradation in dif-
erent cell types, and phosphorylation by mTORC2 at S473 can de-
rease AKT stability in addition to allowing full kinase activation
47,74]. Of note, Pin1, a known modulator of protein folding, ac-
ivity and stability [45] and a relevant player in cardiac hypertro-
hy [48] and cardiac calcium handling [75], reportedly acts as a
ey positive factor in the regulation of AKT stability in cancer cells
y binding to Ser473-activated AKT and protecting it from degra-ation by the proteasome, so decreased Pin1 expression facilitates
KT degradation [46,47]. Pin1 can also be degraded by the pro-
easome [76,77], and decreased expression takes place in liver I/R
y unknown mechanisms [78]). GRK2 controls Pin1 stability and
unctionality in cancer cells by modulating its acetylation status
ia HDAC6, so decreased GRK2 expression fosters Pin1 acetylation
nd favors its degradation [30]. Consistently, we find that cardiac
RK2 downregulation during I/R correlates with a marked reduc-
ion in total Pin1 levels, along with its enhanced acetylation. Such
ecrease in this AKT stabilizing factor would in turn facilitate the
bserved concurrent AKT degradation.
Supporting a potential clinical relevance of our findings, a pat-
ern of concomitant down-modulation of GRK2/AKT/Pin1 protein
evels in early stages of cardiac I/R was also observed in pigs,
very relevant large animal model used in translational studies
28,51,79]. One limitation of our study is the relatively low number
f animals per condition, arising from the logistic complexity of
his type of experiments, including comparison of expression levels
uring myocardial ischemia and different early time points follow-
ng reperfusion, as well as pre- or post-conditioning conditions in
he rat model, However, the fact that the key changes reported are
bserved at different time points, in independent experiments in
ther rat cohorts using calpain and proteasome inhibitors and in a
arge animal pig model support the main conclusions of this work.
Consistent with this notion of related proteolysis events of
RK2 (via both proteasome and calpains), Pin1 and AKT (mostly
ia proteasome) during I/R, the combined inhibition of these
egradation pathways prior to I/R fully prevents the degradation
f GRK2, Pin1 and AKT, rescues global AKT functionality in rat car-
iac extracts, and significantly decreases infarct size and LDH re-
ease. Both calpain [42–44] and the proteasome [80,81] have been
eported to target a variety of cardiac substrates, including com-
onents of several signaling cascades. The susceptibility of specific
ubstrates for degradation may vary depending on their subcel-
ular localization, whereas different proteasome inhibitors inhibit
ardiac proteasome subtypes to a different extent [82]. Thus, it is
ikely that the combined effect of SNJ-1945 and bortezomib may
lter the levels of other cardiac signaling pathways in addition to
he GRK2/Pin1/AKT axis. However, the fact that the protective ef-
ect of these inhibitors in I/R-induced cardiac damage is lost in the
resence of an inhibitor of the PI3K/Akt pathway strongly suggests
hat preventing GRK2/Pin1/AKT degradation in cardiac cell types at
arly times in I/R and the parallel rescue of global AKT functional-
ty play a relevant role in helping reduce myocardial injury.
Our observation that AKT protein levels fall during early I/R, re-
ulting in an overall decrease of the functionality of this key car-
ioprotective pathway despite the stimulated status of the remain-
ng AKT upon reperfusion puts forward a strong impediment for
reatment approaches aimed only to enhance AKT activation sta-
us, as is the case for a variety of conditioning and pharmacologi-
al strategies [1,4,9–11], and suggest that treatments using a com-
ination of calpain and proteasome inhibitors at the time of flow
estoration in order to inhibit GRK2 and AKT degradation would
oster the efficacy of endogenous cardioprotection, cardioprotective
rugs or conditioning strategies.
In addition to helping preserve global AKT functionality, shield-
ng GRK2 from degradation during early reperfusion might also
rotect against malignant ventricular tachyarrhythmias [53–55]
nd adrenergic-mediated myocardial injury [38]. However, given
he reported increase in GRK2 expression at later time points
fter MI and their overall maladaptive role in cardiac remodel-
ng and progression to HF [12,13,15,16,23], the therapeutic win-
ow for strategies aimed at decreasing GRK2 degradation should
e carefully established. In mouse models, genetic GRK2 ablation
0days after MI [83] or treatment with the GRK2 catalytic in-
ibitor paroxetine initiated 2weeks after MI [22] improved cardiac
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Rfunction and reduced the adverse remodeling of ischemic nature.
In this regard, permanent down-regulation of GRK2 in cardiac-
specific knock-out animals protects [18], whereas increased GRK2
protein levels in cardiac transgenic GRK2 mice at the onset of
MI aggravates [84] the injury caused by I/R, reportedly related to
pro-apoptotic signaling triggered by enhanced targeting of GRK2
to the mitochondrial compartment, likely initiated during the is-
chemic phase of MI injury, as GRK2 mitochondrial shuttling de-
pends on S670 phosphorylation, which is induced by ischemia. Al-
though such data are consistent with a maladaptive role of high
GRK2 levels in the long term, these models do not recapitulate
the dynamic changes in GRK2 levels occurring at different phases
of ischemia/reperfusion/remodeling and do not rule out a protec-
tive role for timely prevention of GRK2 degradation at early points
of reperfusion. Interestingly, adenoviral delivery or cardiac trans-
genic expression of the C-terminal region of GRK2 (βARKct con-
struct, aa 495–689) has a clear cardio-protective effect in both HF
and acute MI experimental settings in murine or porcine preclini-
cal models, by mechanisms involving prevention of the interaction
and activation of GRK2 by Gβγ subunits released upon GPCR acti-
vation and interference with GRK2 phosphorylation at Ser670 and
maladaptive targeting to mitochondria (reviewed in [13,21,23]). In
other cell types, expression of βARKct also inhibits phosphoryla-
tion of endogenous GRK2 at Ser-670 by CDK2 and Pin1/GRK2 asso-
ciation, thus preventing down-regulation of endogenous GRK2 dur-
ing cell cycle progression [31]. It is thus tempting to suggest that in
the cardiac context an additional therapeutic effect of the ectopic
expression of βARKct (which bears both the Ser670 and Ser685-
related GRK2 phosphodegrons, highly conserved across species)
would be to compete with endogenous GRK2 in the phosphory-
lation by the respective kinases and the action of the degradation
machinery during I/R. Therefore, βARKct would contribute to the
stabilization of the full-length endogenous GRK2 protein and thus
of its cardioprotective Pin1 and AKT partners in the early phase
after acute myocardial injury, while still acting as a modulator of
GRK2 subcellular distribution and as a potent inhibitor of GRK2
functionality once the maladaptive increase in GRK2 takes place at
later stages.
In sum, our data uncover dynamic changes in the central GRK2
and AKT cardiac signaling nodes at early stages after I/R, and sug-
gest that the timely use of calpain and proteasome inhibition in
these contexts may be an amenable way to reinforce therapeutic
strategies aimed at reducing I/R injury.
Funding
ISCIII, CIBERCV, MINECO Spain, Fundación Areces.
Author contributions
PP and JI designed and performed experiments, prepared fig-
ures, analyzed data, wrote and revised manuscript, ARS provided
cardiac pig samples and analyzed data, PR performed experiments,
analyzed data and prepared figures, DG-D and FM Jr., provided
study concept and design, interpreted experiments, analyzed data,
supervised the study, wrote and revised manuscript.
Acknowledgements and funding sources
Our laboratories are supported by Instituto de Salud Carlos III,
Spain (grant PI-16/00232; RETICS-RIC-RD12/0042/0021 to DGD, co-
funded with European Regional Development Fund-FEDER contri-
bution, and grants PI14-00435 and PI17-00576 to PP), by Ministerio
de Economía; Industria y Competitividad (MINECO) of Spain (grant
SAF2017-84125-R to F.M.); by CIBERCV-Instituto de Salud Carlos III,pain (grant CB16/11/00479 to DGD and CB16/11/00278 to F.M, co-
unded with European Regional Development Fund-FEDER contri-
ution), and Programa de Actividades en Biomedicina de la Co-
unidad de Madrid-B2017/BMD-3671-INFLAMUNE to F.M. We also
cknowledge institutional support to the CBMSO from Fundación
amón Areces. This work is dedicated to the memory of our col-
eague and friend Dr. David García-Dorado, who sadly passed away
uring the final revision stage of this manuscript.
eclaration of Competing Interest
The authors have nothing to disclose.
ppendix A. Supplementary data
Supplementary data to this article can be found online at https:
/doi.org/10.1016/j.ebiom.2019.09.019.
eferences
[1] Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected
therapeutic target. J Clin Invest 2013;123(1):92–100.
[2] Ibanez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial
ischemia/reperfusion injury. J Am Coll Cardiol 2015;65(14):1454–71.
[3] Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Car-
diovasc Res 1998;38(2):291–300.
[4] Heusch G, Libby P, Gersh B, Yellon D, Bohm M, Lopaschuk G, et al. Car-
diovascular remodelling in coronary artery disease and heart failure. Lancet.
2014;383(9932):1933–43.
[5] Garcia-Dorado D, Rodriguez-Sinovas A, Ruiz-Meana M, Inserte J. Protection
against myocardial ischemia-reperfusion injury in clinical practice. Rev Esp
Cardiol 2014;67(5):394–404.
[6] Binek A, Fernandez-Jimenez R, Jorge I, Camafeita E, Lopez JA, Bagwan N,
et al. Proteomic footprint of myocardial ischemia/reperfusion injury: longi-
tudinal study of the at-risk and remote regions in the pig model. Sci Rep
2017;7(1):12343.
[7] Fuster V. Top 10 cardiovascular therapies and interventions for the next
decade. Nat Rev Cardiol 2014;11(11):671–83.
[8] Davidson SM, Ferdinandy P, Andreadou I, Botker HE, Heusch G, Ibanez B,
et al. Multitarget strategies to reduce myocardial ischemia/reperfusion injury:
JACC review topic of the week. J Am Coll Cardiol 2019;73(1):89–99.
[9] Hausenloy DJ, Yellon DM. Ischaemic conditioning and reperfusion injury. Nat
Rev Cardiol 2016;13(4):193–209.
[10] Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic
pre-, post-, and remote conditioning. Circ Res 2015;116(4):674–99.
[11] Rossello X, Riquelme JA, Davidson SM, Yellon DM. Role of PI3K in myocardial
ischaemic preconditioning: mapping pro-survival cascades at the trigger phase
and at reperfusion. J Cell Mol Med 2018;22(2):926–35.
[12] Woodall MC, Ciccarelli M, Woodall BP, Koch WJ. G protein-coupled recep-
tor kinase 2: a link between myocardial contractile function and cardiac
metabolism. Circ Res 2014;114(10):1661–70.
[13] Sato PY, Chuprun JK, Schwartz M, Koch WJ. The evolving impact of g pro-
tein-coupled receptor kinases in cardiac health and disease. Physiol Rev
2015;95(2):377–404.
[14] Cannavo A, Koch WJ. GRK2 as negative modulator of NO bioavailability: impli-
cations for cardiovascular disease. Cell Signal 2018;41:33–40.
[15] Mayor F Jr, Cruces-Sande M, Arcones AC, Vila-Bedmar R, Briones AM,
Salaices M, et al. G protein-coupled receptor kinase 2 (GRK2) as an integra-
tive signalling node in the regulation of cardiovascular function and metabolic
homeostasis. Cell Signal 2018;41:25–32.
[16] Murga C, Arcones AC, Cruces-Sande M, Briones AM, Salaices M, Mayor F Jr. G
protein-coupled receptor kinase 2 (GRK2) as a potential therapeutic target in
cardiovascular and metabolic diseases. Front Pharmacol 2019;10:112.
[17] Nogues L, Palacios-Garcia J, Reglero C, Rivas V, Neves M, Ribas C, et al. G pro-
tein-coupled receptor kinases (GRKs) in tumorigenesis and cancer progression:
GPCR regulators and signaling hubs. Semin Cancer Biol 2018;48:78–90.
[18] Fan Q, Chen M, Zuo L, Shang X, Huang MZ, Ciccarelli M, et al. Myocar-
dial ablation of G protein-coupled receptor kinase 2 (GRK2) decreases is-
chemia/reperfusion injury through an anti-intrinsic apoptotic pathway. PLoS
One 2013;8(6):e66234.
[19] Sato PY, Chuprun JK, Grisanti LA, Woodall MC, Brown BR, Roy R, et al. Re-
stricting mitochondrial GRK2 post-ischemia confers cardioprotection by reduc-
ing myocyte death and maintaining glucose oxidation. Sci Signal 2018;11(560).
[20] Penela P, Murga C, Ribas C, Tutor AS, Peregrin S, Mayor F Jr. Mechanisms of
regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular
disease. Cardiovasc Res 2006;69(1):46–56.
[21] de Lucia C, Eguchi A, Koch WJ. New insights in cardiac beta-adrenergic signal-
ing during heart failure and aging. Front Pharmacol 2018;9:904.
[22] Schumacher SM, Gao E, Zhu W, Chen X, Chuprun JK, Feldman AM, et al. Parox-
etine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling
after myocardial infarction. Sci Transl Med 2015;7(277):277ra31.
P. Penela, J. Inserte and P. Ramos et al. / EBioMedicine 48 (2019) 605–618 617
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[23] Cannavo A, Komici K, Bencivenga L, D’Amico ML, Gambino G, Liccardo D,
et al. GRK2 as a therapeutic target for heart failure. Expert Opin Ther Targets
2018;22(1):75–83.
[24] Inserte J, Garcia-Dorado D, Hernando V, Barba I, Soler-Soler J. Ischemic pre-
conditioning prevents calpain-mediated impairment of Na+/K+-ATPase activity
during early reperfusion. Cardiovasc Res 2006;70(2):364–73.
25] Inserte J, Barba I, Hernando V, Garcia-Dorado D. Delayed recovery of intracel-
lular acidosis during reperfusion prevents calpain activation and determines
protection in postconditioned myocardium. Cardiovasc Res 2009;81(1):116–22.
26] Inserte J, Hernando V, Vilardosa U, Abad E, Poncelas-Nozal M, Garcia-Dorado D.
Activation of cGMP/protein kinase G pathway in postconditioned myocardium
depends on reduced oxidative stress and preserved endothelial nitric oxide
synthase coupling. J Am Heart Assoc 2013;2(1):e005975.
[27] Poncelas M, Inserte J, Aluja D, Hernando V, Vilardosa U, Garcia-Dorado D. De-
layed, oral pharmacological inhibition of calpains attenuates adverse post-in-
farction remodelling. Cardiovasc Res 2017;113(8):950–61.
28] Alburquerque-Bejar JJ, Barba I, Inserte J, Miro-Casas E, Ruiz-Meana M, Pon-
celas M, et al. Combination therapy with remote ischaemic conditioning and
insulin or exenatide enhances infarct size limitation in pigs. Cardiovasc Res
2015;107(2):246–54.
29] Penela P, Ruiz-Gomez A, Castano JG, Mayor F Jr. Degradation of the G pro-
tein-coupled receptor kinase 2 by the proteasome pathway. J Biol Chem
1998;273(52):35238–44.
30] Nogues L, Reglero C, Rivas V, Salcedo A, Lafarga V, Neves M, et al. G protein–
coupled receptor kinase 2 (GRK2) promotes breast tumorigenesis through a
HDAC6-Pin1 axis. EBioMedicine. 2016;13:132–45.
[31] Penela P, Rivas V, Salcedo A, Mayor F Jr. G protein-coupled receptor kinase
2 (GRK2) modulation and cell cycle progression. Proc Natl Acad Sci U S A
2010;107(3):1118–23.
32] Murga C, Penela P, Zafra F, Mayor F Jr. The subcellular and cellular dis-
tribution of G protein-coupled receptor kinase 2 in rat brain. Neuroscience.
1998;87(3):631–7.
[33] Ferrera R, Benhabbouche S, Bopassa JC, Li B, Ovize M. One hour reperfusion is
enough to assess function and infarct size with TTC staining in Langendorff rat
model. Cardiovasc Drugs Ther 2009;23(4):327–31.
34] Inserte J, Hernando V, Ruiz-Meana M, Poncelas-Nozal M, Fernandez C, Ag-
ullo L, et al. Delayed phospholamban phosphorylation in post-conditioned
heart favours Ca2+ normalization and contributes to protection. Cardiovasc Res
2014;103(4):542–53.
[35] Elorza A, Penela P, Sarnago S, Mayor F Jr. MAPK-dependent degradation of G
protein-coupled receptor kinase 2. J Biol Chem 2003;278(31):29164–73.
36] Penela P, Murga C, Ribas C, Lafarga V, Mayor F Jr. The complex G protein–
coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological
targets. Br J Pharmacol 2010;160(4):821–32.
[37] Cong M, Perry SJ, Lin FT, Fraser ID, Hu LA, Chen W, et al. Regulation of mem-
brane targeting of the G protein-coupled receptor kinase 2 by protein kinase
A and its anchoring protein AKAP79. J Biol Chem 2001;276(18):15192–9.
38] Schreckenberg R, Bencsik P, Weber M, Abdallah Y, Csonka C, Gomori K,
et al. Adverse effects on beta-adrenergic receptor coupling: ischemic post-
conditioning failed to preserve long-term cardiac function. J Am Heart Assoc
2017;6(12).
39] Johnston AS, Lehnart SE, Burgoyne JR. Ca(2+) signaling in the myocardium by
(redox) regulation of PKA/CaMKII. Front Pharmacol 2015;6:166.
40] Nogues L, Salcedo A, Mayor F Jr, Penela P. Multiple scaffolding functions of
{beta}-arrestins in the degradation of G protein-coupled receptor kinase 2. J
Biol Chem 2011;286(2):1165–73.
[41] Penela P, Elorza A, Sarnago S, Mayor F Jr. Beta-arrestin- and c-Sr-
c-dependent degradation of G-protein-coupled receptor kinase 2. EMBO J
2001;20(18):5129–38.
42] Hernando V, Inserte J, Sartorio CL, Parra VM, Poncelas-Nozal M, Garcia-Do-
rado D. Calpain translocation and activation as pharmacological targets during
myocardial ischemia/reperfusion. J Mol Cell Cardiol 2010;49(2):271–9.
43] Aluja D, Inserte J, Penela P, Ramos P, Ribas C, Iniguez MA, et al. Calpains medi-
ate isoproterenol-induced hypertrophy through modulation of GRK2. Basic Res
Cardiol 2019;114(3):21.
44] Inserte J. Calpains in the cardiovascular system. Cardiovasc Res
2012;96(1):9–10.
45] Zhou XZ, Lu KP. The isomerase PIN1 controls numerous cancer-driving path-
ways and is a unique drug target. Nat Rev Cancer 2016;16(7):463–78.
46] Liao Y, Wei Y, Zhou X, Yang JY, Dai C, Chen YJ, et al. Peptidyl-prolyl cis/trans
isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation
phosphorylation. Oncogene. 2009;28(26):2436–45.
[47] Liao Y, Hung MC. Physiological regulation of Akt activity and stability. Am J
Transl Res 2010;2(1):19–42.
48] Toko H, Konstandin MH, Doroudgar S, Ormachea L, Joyo E, Joyo AY, et al. Reg-
ulation of cardiac hypertrophic signaling by prolyl isomerase Pin1. Circ Res
2013;112(9):1244–52.
49] Lafarga V, Aymerich I, Tapia O, Mayor F Jr, Penela P. A novel GRK2/HDAC6 in-
teraction modulates cell spreading and motility. EMBO J 2012;31(4):856–69.
50] Hausenloy DJ, Iliodromitis EK, Andreadou I, Papalois A, Gritsopoulos G, Anas-
tasiou-Nana M, et al. Investigating the signal transduction pathways underly-
ing remote ischemic conditioning in the porcine heart. Cardiovasc Drugs Ther
2012;26(2):87–93.
[51] Gent S, Skyschally A, Kleinbongard P, Heusch G. Lschemic preconditioning in
pigs: a causal role for signal transducer and activator of transcription 3. Am J
Physiol Heart Circ Physiol 2017;312(3) (H478-H84).52] White DC, Hata JA, Shah AS, Glower DD, Lefkowitz RJ, Koch WJ. Preser-
vation of myocardial beta-adrenergic receptor signaling delays the develop-
ment of heart failure after myocardial infarction. Proc Natl Acad Sci U S A
2000;97(10):5428–33.
53] Yu X, Zhang M, Kyker K, Patterson E, Benovic JL, Kem DC. Ischemic in-
activation of G protein-coupled receptor kinase and altered desensitization
of canine cardiac beta-adrenergic receptors. Circulation. 2000;102(20):2535–
2540.
54] Yu X, Huang S, Patterson E, Garrett MW, Kaufman KM, Metcalf JP, et al. Protea-
some degradation of GRK2 during ischemia and ventricular tachyarrhythmias
in a canine model of myocardial infarction. Am J Physiol Heart Circ Physiol
2005;289(5):H1960–7.
55] Huang S, Patterson E, Yu X, Garrett MW, De Aos I, Kem DC. Proteasome inhibi-
tion 1 h following ischemia protects GRK2 and prevents malignant ventricular
tachyarrhythmias and SCD in a model of myocardial infarction. Am J Physiol
Heart Circ Physiol 2008;294(3):H1298–303.
56] Lombardi MS, van den Tweel E, Kavelaars A, Groenendaal F, van Bel F, Heij-
nen CJ. Hypoxia/ischemia modulates G protein-coupled receptor kinase 2 and
beta-arrestin-1 levels in the neonatal rat brain. Stroke. 2004;35(4):981–6.
[57] Lombardi MS, Vroon A, Sodaar P, van Muiswinkel FL, Heijnen CJ, Kave-
laars A. Down-regulation of GRK2 after oxygen and glucose deprivation
in rat hippocampal slices: role of the PI3-kinase pathway. J Neurochem
2007;102(3):731–40.
58] Ungerer M, Kessebohm K, Kronsbein K, Lohse MJ, Richardt G. Activation
of beta-adrenergic receptor kinase during myocardial ischemia. Circ Res
1996;79(3):455–60.
59] Elorza A, Sarnago S, Mayor F Jr. Agonist-dependent modulation of G protein–
coupled receptor kinase 2 by mitogen-activated protein kinases. Mol Pharma-
col 2000;57(4):778–83.
60] Penela P, Murga C, Ribas C, Salcedo A, Jurado-Pueyo M, Rivas V, et al. G pro-
tein-coupled receptor kinase 2 (GRK2) in migration and inflammation. Arch
Physiol Biochem 2008;114(3):195–200.
[61] Liu X, Ma B, Malik AB, Tang H, Yang T, Sun B, et al. Bidirectional regulation
of neutrophil migration by mitogen-activated protein kinases. Nat Immunol
2012;13(5):457–64.
62] Liem DA, Zhao P, Angelis E, Chan SS, Zhang J, Wang G, et al. Cyclin-dependent
kinase 2 signaling regulates myocardial ischemia/reperfusion injury. J Mol Cell
Cardiol 2008;45(5):610–16.
63] Neuhof C, Neuhof H. Calpain system and its involvement in myocardial is-
chemia and reperfusion injury. World J Cardiol 2014;6(7):638–52.
64] Inserte J, Garcia-Dorado D, Ruiz-Meana M, Agullo L, Pina P, Soler-Soler J. Is-
chemic preconditioning attenuates calpain-mediated degradation of structural
proteins through a protein kinase A-dependent mechanism. Cardiovasc Res
2004;64(1):105–14.
65] Diviani D, Reggi E, Arambasic M, Caso S, Maric D. Emerging roles of A-kinase
anchoring proteins in cardiovascular pathophysiology. Biochim Biophys Acta
2016;1863(7):1926–36 Pt B.
66] Brennan JP, Bardswell SC, Burgoyne JR, Fuller W, Schroder E, Wait R, et al. Ox-
idant-induced activation of type I protein kinase A is mediated by RI sub-
unit interprotein disulfide bond formation. J Biol Chem 2006;281(31):21827–
21836.
[67] Yi XP, Gerdes AM, Li F. Myocyte redistribution of GRK2 and GRK5 in hyperten-
sive, heart-failure-prone rats. Hypertension. 2002;39(6):1058–63.
68] Cadenas S. ROS and redox signaling in myocardial ischemia-reperfusion injury
and cardioprotection. Free Radic Biol Med 2018;117:76–89.
69] Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D, et al. Is-
chemic postconditioning in pigs: no causal role for RISK activation. Circ Res
2009;104(1):15–18.
[70] Skyschally A, Gent S, Amanakis G, Schulte C, Kleinbongard P, Heusch G.
Across-species transfer of protection by remote ischemic preconditioning
with species-specific myocardial signal transduction by reperfusion injury sal-
vage kinase and survival activating factor enhancement pathways. Circ Res
2015;117(3):279–88.
[71] Yin Z, Gao H, Wang H, Li L, Di C, Luan R, et al. Ischaemic post-conditioning
protects both adult and aged Sprague-Dawley rat heart from ischaemia-reper-
fusion injury through the phosphatidylinositol 3-kinase-AKT and glycogen syn-
thase kinase-3beta pathways. Clin Exp Pharmacol Physiol 2009;36(8):756–63.
[72] Moreira JB, Wohlwend M, Alves MN, Wisloff U, Bye A. A small molecule ac-
tivator of AKT does not reduce ischemic injury of the rat heart. J Transl Med
2015;13:76.
[73] Kleinbongard P, Skyschally A, Gent S, Pesch M, Heusch G. STAT3 as a common
signal of ischemic conditioning: a lesson on "rigor and reproducibility" in pre-
clinical studies on cardioprotection. Basic Res Cardiol 2018;113(1):3.
[74] Wu YT, Ouyang W, Lazorchak AS, Liu D, Shen HM, Su B. mTOR complex 2 tar-
gets Akt for proteasomal degradation via phosphorylation at the hydrophobic
motif. J Biol Chem 2011;286(16):14190–8.
75] Sacchi V, Wang BJ, Kubli D, Martinez AS, Jin JK, Alvarez R Jr, et al. Peptidyl-pro-
lyl isomerase 1 regulates Ca(2+) handling by modulating Sarco(Endo)Plasmic
reticulum calcium ATPase and Na(2+)/Ca(2+) exchanger 1 protein levels and
function. J Am Heart Assoc 2017;6(10).
[76] Basu A, Das M, Qanungo S, Fan XJ, DuBois G, Haldar S. Proteasomal degrada-
tion of human peptidyl prolyl isomerase pin1-pointing phospho Bcl2 toward
dephosphorylation. Neoplasia. 2002;4(3):218–27.
[77] Eckerdt F, Yuan J, Saxena K, Martin B, Kappel S, Lindenau C, et al. Polo-like
kinase 1-mediated phosphorylation stabilizes Pin1 by inhibiting its ubiquitina-
tion in human cells. J Biol Chem 2005;280(44):36575–83.
618 P. Penela, J. Inserte and P. Ramos et al. / EBioMedicine 48 (2019) 605–618[78] Kuboki S, Okaya T, Schuster R, Blanchard J, Denenberg A, Wong HR, et al. Hep-
atocyte NF-kappaB activation is hepatoprotective during ischemia-reperfusion
injury and is augmented by ischemic hypothermia. Am J Physiol Gastrointest
Liver Physiol 2007;292(1):G201–7.
[79] Raake PW, Schlegel P, Ksienzyk J, Reinkober J, Barthelmes J, Schinkel S,
et al. AAV6.betaARKct cardiac gene therapy ameliorates cardiac function and
normalizes the catecholaminergic axis in a clinically relevant large animal
heart failure model. Eur Heart J 2013;34(19):1437–47.
[80] Pagan J, Seto T, Pagano M, Cittadini A. Role of the ubiquitin proteasome system
in the heart. Circ Res 2013;112(7):1046–58.
[81] Glembotski CC. Clarifying the cardiac proteasome paradox: protein quality con-
trol. Circ Res 2012;111(5):509–12.[82] Kloss A, Meiners S, Ludwig A, Dahlmann B. Multiple cardiac proteasome sub-
types differ in their susceptibility to proteasome inhibitors. Cardiovasc Res
2010;85(2):367–75.
[83] Raake PW, Vinge LE, Gao E, Boucher M, Rengo G, Chen X, et al. G pro-
tein-coupled receptor kinase 2 ablation in cardiac myocytes before or af-
ter myocardial infarction prevents heart failure. Circ Res 2008;103(4):413–
422.
[84] Brinks H, Boucher M, Gao E, Chuprun JK, Pesant S, Raake PW, et al. Level of G
protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion
injury via pro- and anti-apoptotic mechanisms. Circ Res 2010;107(9):1140–
1149.
